 |
|
|
|
 |
|
|
| Article 1 to 10 out of 22 concerning Boehringer Ingelheim GmbH
|
-
Boehringer Ingelheim gains access to additional MorphoSys technology
(07/11/2008)
MorphoSys AG announced that Boehringer Ingelheim has exercised a pre-existing option to use MorphoSys's proprietary RapMAT technology for faster antibody optimization as part of the existing technology transfer agreement between the two companies. ...
-
BIOMEVA and Boehringer Ingelheim strengthen their biomanufacturing services in a production alliance
(11/19/2007)
BIOMEVA GmbH and Boehringer Ingelheim announced that both companies have entered into a production alliance agreement. With this collaboration BIOMEVA GmbH may have non-exclusive access to Boehringer Ingelheim's comprehensive manufacturing ...
-
Ablynx and Boehringer Ingelheim announce global strategic alliance to discover, develop and commercialise Nanobody therapeutics
(09/11/2007)
Boehringer Ingelheim and Ablynx jointly announced a major global strategic alliance to discover, develop and commercialise up to 10 different Nanobody® therapeutics. Ablynx expects to receive payments of EUR 75 million during the research term of ...
-
Galapagos announces milestone in collaboration with Boehringer Ingelheim
(07/23/2007)
The three-year collaboration announced in January 2006 involves an expansion of BioFocus DPI's SilenceSelect® sh-RNA based gene collection with an additional gene set, the development of a dedicated cellular assay in the field of autoimmune ...
-
Ablynx and Boehringer Ingelheim sign $265 million research and licensing agreement to develop new Alzheimer's treatments
(01/10/2007)
Boehringer Ingelheim and Ablynx have jointly announced an exclusive worldwide collaboration and licence agreement worth almost $265 million to discover and develop new therapies for Alzheimer's disease using Ablynx' Nanobodies®, a novel class of ...
-
Boehringer Ingelheim Pharmaceuticals expands drug discovery alliance with Graffinity
(12/15/2006)
Graffinity Pharmaceuticals GmbH announced that its partner Boehringer Ingelheim Pharmaceuticals, Inc. has chosen to exercise options in its original agreement with Graffinity that will significantly increase the number of targets screened by ...
-
Graffinity and Boehringer Ingelheim Pharmaceuticals enter into drug discovery research agreement
(09/11/2006)
Graffinity Pharmaceuticals GmbH announced that it has entered into a research collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. which involves four global research sites of Boehringer Ingelheim. Under the terms of the agreement, ...
-
genOway and Boehringer Ingelheim reinforce their collaboration
(07/10/2006)
genOway reports a collaboration with Boehringer Ingelheim for the development of experimental research models. This collaboration has been recently reinforced and now includes several innovative technological solutions developed by genOway to create ...
-
Evotec and Boehringer Ingelheim Significantly Expand and Extend their Joint Drug Discovery Collaboration
(01/18/2006)
Evotec AG announced that effective from 1 January 2006 Evotec and Boehringer Ingelheim GmbH will significantly expand their drug discovery collaboration initiated in September 2004, effectively doubling the already sizeable programme. At the same ...
-
Galapagos enters new collaboration in autoimmune discovery research
(01/17/2006)
BioFocus, the service division of Galapagos, announced a new three year collaboration in the field of autoimmune discovery research. Under the terms of the agreement, BioFocus will expand its SilenceSelect® si-RNA based gene collection with an ...
Additional information
Boehringer Ingelheim GmbH
Ingelheim, Germany
Company
|
|
|
|
|
|
Top
